Forte Biosciences (FBRX) Competitors $15.89 -0.07 (-0.44%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$15.89 0.00 (0.00%) As of 01/31/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends FBRX vs. INZY, LPTX, CLLS, CUE, ENTX, SCLX, DERM, JSPR, KPTI, and XFORShould you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Inozyme Pharma (INZY), Leap Therapeutics (LPTX), Cellectis (CLLS), Cue Biopharma (CUE), Entera Bio (ENTX), Scilex (SCLX), Journey Medical (DERM), Jasper Therapeutics (JSPR), Karyopharm Therapeutics (KPTI), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry. Forte Biosciences vs. Inozyme Pharma Leap Therapeutics Cellectis Cue Biopharma Entera Bio Scilex Journey Medical Jasper Therapeutics Karyopharm Therapeutics X4 Pharmaceuticals Forte Biosciences (NASDAQ:FBRX) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Do analysts prefer FBRX or INZY? Forte Biosciences presently has a consensus price target of $23.58, indicating a potential upside of 48.42%. Inozyme Pharma has a consensus price target of $18.33, indicating a potential upside of 1,173.15%. Given Inozyme Pharma's higher possible upside, analysts clearly believe Inozyme Pharma is more favorable than Forte Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Inozyme Pharma 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of FBRX or INZY? 77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are held by institutional investors. 3.1% of Forte Biosciences shares are held by company insiders. Comparatively, 11.2% of Inozyme Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, FBRX or INZY? Forte Biosciences has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Which has preferable earnings & valuation, FBRX or INZY? Forte Biosciences is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$31.48M-$16.29-0.98Inozyme PharmaN/AN/A-$71.17M-$1.56-0.92 Does the MarketBeat Community believe in FBRX or INZY? Inozyme Pharma received 25 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 87.30% of users gave Inozyme Pharma an outperform vote while only 61.22% of users gave Forte Biosciences an outperform vote. CompanyUnderperformOutperformForte BiosciencesOutperform Votes3061.22% Underperform Votes1938.78% Inozyme PharmaOutperform Votes5587.30% Underperform Votes812.70% Is FBRX or INZY more profitable? Inozyme Pharma's return on equity of -88.42% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -151.43% -118.92% Inozyme Pharma N/A -88.42%-57.02% Does the media refer more to FBRX or INZY? In the previous week, Forte Biosciences had 1 more articles in the media than Inozyme Pharma. MarketBeat recorded 3 mentions for Forte Biosciences and 2 mentions for Inozyme Pharma. Forte Biosciences' average media sentiment score of 0.63 beat Inozyme Pharma's score of 0.44 indicating that Forte Biosciences is being referred to more favorably in the media. Company Overall Sentiment Forte Biosciences Positive Inozyme Pharma Neutral SummaryInozyme Pharma beats Forte Biosciences on 11 of the 14 factors compared between the two stocks. Get Forte Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBRX vs. The Competition Export to ExcelMetricForte BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.20M$6.86B$5.56B$9.11BDividend YieldN/A2.90%5.31%3.98%P/E Ratio-0.989.9789.9918.25Price / SalesN/A287.751,242.1483.63Price / CashN/A73.5045.9637.70Price / Book0.655.275.124.71Net Income-$31.48M$136.98M$111.09M$224.24M7 Day Performance4.95%-0.62%2.38%1.08%1 Month Performance-30.03%0.15%3.20%1.51%1 Year PerformanceN/A7.68%24.70%20.44% Forte Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBRXForte Biosciences3.9228 of 5 stars$15.89-0.4%$23.58+48.4%+65,012.3%$21.42MN/A-0.985Short Interest ↓Gap UpINZYInozyme Pharma3.35 of 5 stars$1.36-3.9%$18.33+1,253.0%-73.8%$87.69MN/A-0.8750Short Interest ↑Gap UpLPTXLeap Therapeutics1.7027 of 5 stars$2.26+5.1%$7.50+231.9%-81.3%$86.60MN/A-1.1740Analyst DowngradeAnalyst RevisionNews CoverageCLLSCellectis3.698 of 5 stars$1.56-6.9%$7.00+350.2%-46.3%$86.43M$9.19M-1.20290Short Interest ↓CUECue Biopharma4.6811 of 5 stars$1.38-7.4%$5.00+262.6%-45.1%$86.16M$5.49M-1.5160Short Interest ↓Gap DownENTXEntera Bio2.4798 of 5 stars$2.40-0.2%$10.00+317.5%+163.9%$85.69M$130,000.00-9.2120Short Interest ↓News CoverageSCLXScilex3.697 of 5 stars$0.44+0.1%$14.00+3,074.6%-74.9%$84.58M$46.74M-0.5380Gap DownDERMJourney Medical2.5437 of 5 stars$4.04-3.0%$9.38+132.3%N/A$84.29M$79.18M-4.2990Short Interest ↑News CoverageJSPRJasper Therapeutics2.6608 of 5 stars$5.61-1.5%$67.75+1,106.8%-48.6%$84.23MN/A-1.1820Short Interest ↑KPTIKaryopharm Therapeutics4.0016 of 5 stars$0.66-5.4%$5.00+655.3%-17.1%$83.79M$146.03M-0.58380XFORX4 Pharmaceuticals4.3172 of 5 stars$0.49+2.8%$3.50+612.8%-10.4%$83.74MN/A-5.4580Gap Down Related Companies and Tools Related Companies INZY Competitors LPTX Competitors CLLS Competitors CUE Competitors ENTX Competitors SCLX Competitors DERM Competitors JSPR Competitors KPTI Competitors XFOR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FBRX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
